Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Sep 28, 2022 4:22pm

200 Views

Post# 34993259

RE:RE:RE:RE:Adlai Nortye

Yes. I see your point about a change. Perhaps when they stopped recruiting or any number of other things. It seems to me (and I could be wrong) that AN and ONC/ONCY are if anything closer than say a few months ago. This is the time for those at the corporate level to be circumspect.

The recent hires are there to facilitate. To me, if there is a deal in the works, it is complex, and all the info is not in. We wait. Cheers.

PS. One would hope that royalties and milestones are not even on what should be the real agenda.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023